Today there is a lot of news one can access with regard to Roche - running the gamut from an interview with Roche CEO, Severin Schwan to their first investor's conference post-merger with Genentech to reports on their pipeline through 2014.
Mike Huckman interviewed Severin Schwan live this morning on CNBC (video).
Roche's first investor conference and webinar post-Genentech can be found here.
Finally, Reuter's reports on Roche's pipeline expectations. The company plans to launch 6 new drugs by 2014 and may have up to 35 line extensions. Drugs for diabetes and cardiovascular applications are expected to be first/best in class and blockbusters.
Posted by Bruce Lehr March 18, 2010
Seeking Alpha recently (May 2nd) published a discussion as to whether Roche would be looking to acquire PDL in its family. Roche already hs 4 licenses from PDL for drugs in its oncology portfolio. Stay tuned.
http://seekingalpha.com/article/202235-pdl-biopharma-a-genentech-roche-buyout-candidate
Posted by: Bruce Lehr | 05/02/2010 at 10:01 AM
Here is a link to Roche's late stage pipeline as summarized in Fierce Biotech.
http://www.fiercepharma.com/pages/roches-late-stage-pipeline
Posted by: Bruce Lehr | 03/19/2010 at 02:04 PM